Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world
{{output}}
Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved for... ...
